Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Mentor Graphics Corp. (NASDAQ: MENT) shares increased 3.02 percent to close at $20.46 a share Tuesday. The stock traded between $20.08 and $20.48 on volume of 464,172 shares traded. Analysts at Pacific Crest have recently initiated coverage on the company with an "outperform" rating. Shares of Mentor Graphics have gained approximately 20.0 percent year-to-date.
Find out more about Mentor Graphics including full access to the free equity report at:
www.RDInvesting.com/MENT
National Fuel Gas Co. (NYSE: NFG) shares gained 0.78 percent to close at $64.32 a share Tuesday. The stock traded between $64.01 and $65.63 on volume of 521,466 shares traded. Analysts at Raymond James have recently upgraded the company's rating to "outperform" from "market perform". Shares of National Fuel Gas have fallen approximately 20.0 percent year-to-date.
Find out more about National Fuel Gas including full access to the free equity report at:
www.RDInvesting.com/NFG
Bankrate Inc. (NYSE: RATE) shares surged 17.17 percent to close at $18.49 a share Tuesday. The stock traded between $17.57 and $19.75 on volume of 3.90 million shares traded. Analysts at Bank of America Merrill Lynch have recently upgraded the company's rating to "buy" from "neutral". Shares of Bankrate have gained approximately 48.5 percent year-to-date.
Find out more about Bankrate including full access to the free equity report at:
www.RDInvesting.com/RATE
Stemline Therapeutics Inc. (NASDAQ: STML) shares surged 16.27 percent to close at $27.73 a share Tuesday. The stock traded between $25.21 and $28.16 on volume of 307,015 shares traded. Analysts at Roth Capital have recently initiated coverage on the company with a "buy" rating. Shares of Stemline Therapeutics have gained approximately 127.0 percent year-to-date.
Find out more about Stemline Therapeutics including full access to the free equity report at:
www.RDInvesting.com/STML
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]